TRK-IN-18
TRK-IN-18 is a potent inhibitor of TRK. Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5) . TRK-IN-18 has the potential for the research of cancer diseases (extracted from patent WO2021148805A1, compound 7) [1].
Product Specifications
CAS Number
[2412008-91-2]
UNSPSC
12352005
Target
Trk Receptor
Type
Reference compound
Related Pathways
Neuronal Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/trk-in-18.html
Solubility
10 mM in DMSO
Smiles
CSC1=C(C=C(C=C1)F)[C@H]2C[C@@H](CN2C3=NN4C(C(NCC5=CC(O)=CC=C5)=O)=CN=C4C=C3)F
Molecular Formula
C25H23F2N5O2S
Molecular Weight
495.54
References & Citations
[1]Nicola ROBAS, et al. Topical pharmaceutical compositions comprising imidazo[1,2-b]pyridazine compounds. Paatent WO2021148805A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
NASP, NT (NASP, Nuclear autoantigenic sperm protein) (FITC)
N- (2,5-dimethylphenyl) -3- (4-hydroxy-3-methoxyphenyl) -2- (2H-tetrazol-5-yl) propanamide
![POLDIP1 (KCTD13) Mouse Monoclonal Antibody [Clone ID: OTI1A4]](https://cdn.genprice.uk/genprice/uk/genprice3.webp)